|
Inclusion criteria:
|
|
· Histologically or cytologically confirmed and documented malignant pleural mesothelioma with pleural effusion,
|
|
· Male and Female patients 18 years to 75 years of age,
|
|
· Signed Informed Consent after being informed,
|
|
· Patients medically and/or functionally at screening not accessible for surgical treatment with planned third cycle of palliative chemotherapy in 21 days,
|
|
· Bone marrow function: hemoglobin ≥ 100 g/L; white blood cell count (WBC) ≥ 3.0 x 109/L; absolute neutrophile count (ANC) ≥ 1.5 x 109/L; platelet count ≥ 100 x 109/L,
|
|
· Hepatic: aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 times upper limit of normal (ULN)); bilirubin ≤ 1.5 x ULN,
|
|
· Renal: creatinine ≤ 2 mg/dL and creatinine clearance ≥ 45 mL/min,
|
|
· No concomitant treatment with systemic corticosteroids, or any other immunosuppressive agents,
|
|
· The patient has received no major organ allograft,
|
|
· HIV-negative,
|
|
· HBV and HCV negative,
|
|
· No uncontrolled bleeding disorder,
|
|
· Patients of child-producing potential must agree to use contraception while enrolled in the study and for 24 months after the adoptive transfer.
|
